Related Experiment Video
Updated: Oct 2, 2026
Live-Cell Forward Genetic Approach to Identify and Isolate Developmental Mutants in Chlamydia trachomatis
Published on: June 10, 2020
[Species-specific monoclonal antibodies against the major outer membrane protein (MOMP) of Chlamydia trachomatis]
Abstract:
The synthesized one quarter N-terminal MOMP of C. trachomatis was used for primary immunization of three male BALB/c mice (8 weeks of age), and the boost with C. trachomatis L1/440/Bu elementary bodies (EBs) was followed on day 14. Spleen cells from one mouse with good response of immunization were fused with murine myeloma NS-1 cells on day 24. The hybrid cell suspension was seeded into the wells of 96-well microtest plates which contained macrophage feeder layers. Anti-chlamydial antibodies in culture fluids were screened by ELISA with 1/4 MOMP & L1 EBs coated 96-well trays. Positive wells were cloned by limiting dilution. Four clones which secreted immunoglobulin G1 & G2a class were obtained after elimination of those clones that produced antibodies to C. psittaci strain EAE, C. pneumoniae strain ATCC VR1310 and uninfected BGMK cells. In micro-IF test, we found that the all four clones of MAbs reacted with our laboratory prepared L1, L2, A, B, C, E EBs, L2 tissue culture inclusions, as well as the EBs of all 15 standard serovars of C. trachomatis. The titers of their ascites were more than 1:12,800 in micro-IF test. It was shown that the four clones of MAbs reacted predominantly with 40,000 MOMP of C. trachomatis L1 in Western blot.
Insights
Researchers developed monoclonal antibodies (MAbs) targeting Chlamydia trachomatis. These MAbs effectively detect all 15 serovars, offering a significant advancement in Chlamydia diagnostics and research.
Area of Science:
- Immunology
- Microbiology
- Biotechnology
Background:
- Chlamydia trachomatis is a major cause of bacterial infections worldwide.
- Developing specific diagnostic tools is crucial for effective treatment and control.
- Monoclonal antibodies (MAbs) offer high specificity for pathogen detection.
Purpose of the Study:
- To generate and characterize MAbs against Chlamydia trachomatis.
- To evaluate the reactivity of these MAbs against various Chlamydia serovars and developmental forms.
- To assess the diagnostic potential of the developed MAbs.
Main Methods:
- Immunization of mice with synthesized N-terminal MOMP and elementary bodies (EBs) of C. trachomatis.
- Fusion of spleen cells with myeloma cells to create hybridomas.
- Screening of hybridoma culture fluids using ELISA and indirect immunofluorescence (micro-IF) assays.
- Characterization of MAbs by subclass, specificity testing against related Chlamydia species, and Western blot analysis.
Main Results:
- Four hybridoma clones secreting IgG1 and IgG2a antibodies were successfully generated.
- MAbs demonstrated broad reactivity against EBs and tissue culture inclusions of C. trachomatis serovars L1, L2, A, B, C, and E.
- MAbs reacted with all 15 standard serovars of C. trachomatis in micro-IF tests with high titers (>1:12,800).
- Western blot analysis indicated MAbs predominantly recognized the 40,000 MOMP of C. trachomatis L1.
Conclusions:
- The study successfully produced MAbs with broad reactivity against C. trachomatis.
- These MAbs show potential for use in sensitive and specific diagnostic assays for Chlamydia infections.
- The developed antibodies can aid in research and clinical identification of C. trachomatis infections.
More Related Videos
12:53Cell-Free Scaled Production and Adjuvant Addition to a Recombinant Major Outer Membrane Protein from Chlamydia muridarum for Vaccine Development
Published on: March 16, 2022
06:04Antigen-Capture Enzyme-Linked Immunosorbent Assay for Specific Detection of Mycoplasma pneumoniae
Published on: February 24, 2023
